Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Schaapveld

Showing results (51-60 of 132) with videos related to

Pageof 14
Sort By:
Journal of the National Cancer Institute|February 26, 2015
Risk of valvular heart disease after treatment for Hodgkin lymphomaDavid J Cutter, Michael Schaapveld, Sarah C Darby, et al.
Breast Cancer Research and Treatment|January 28, 2026
Dual-modality breast cancer screening compared to MRI or mammography alone among female Hodgkin lymphoma survivors who received chest radiotherapyEline M J Lammers, Jeanne Beens-van Dijk, Annelies Nijdam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2007
HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphomaArjan Diepstra, Gustaaf W van Imhoff, Henrike E Karim-Kos, et al.
International Journal of Cancer|August 25, 2025
Cause-specific mortality after a diagnosis of ductal carcinoma in situ: Associations with screening and socio-economic statusRenée S J M Schmitz, Alexandra W van den Belt-Dusebout, Maartje van Seijen, et al.
Haematologica|October 20, 2022
Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studiesMax V Boot, Michael Schaapveld, Esther C Van den Broek, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Simple method to estimate mean heart dose from Hodgkin lymphoma radiation therapy according to simulation X-raysFrederika A van Nimwegen, David J Cutter, Michael Schaapveld, et al.
Breast Cancer Research and Treatment|August 10, 2007
The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the NetherlandsMichael Schaapveld, Otto Visser, W J Louwman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2023
Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of LifeSjoukje Lubberts, Harmke J Groot, Ronald de Wit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Risk of diabetes mellitus in long-term survivors of Hodgkin lymphomaFrederika A van Nimwegen, Michael Schaapveld, Cecile P M Janus, et al.
Blood|June 30, 2023
Risk of male breast cancer after Hodgkin lymphomaSimone de Vries, Inge M Krul, Michael Schaapveld, et al.
Pageof 14

Showing results (51-60 of 132) with videos related to

Sort By:
Pageof 14
Journal of the National Cancer Institute|February 26, 2015
Risk of valvular heart disease after treatment for Hodgkin lymphomaDavid J Cutter, Michael Schaapveld, Sarah C Darby, et al.
Breast Cancer Research and Treatment|January 28, 2026
Dual-modality breast cancer screening compared to MRI or mammography alone among female Hodgkin lymphoma survivors who received chest radiotherapyEline M J Lammers, Jeanne Beens-van Dijk, Annelies Nijdam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2007
HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphomaArjan Diepstra, Gustaaf W van Imhoff, Henrike E Karim-Kos, et al.
International Journal of Cancer|August 25, 2025
Cause-specific mortality after a diagnosis of ductal carcinoma in situ: Associations with screening and socio-economic statusRenée S J M Schmitz, Alexandra W van den Belt-Dusebout, Maartje van Seijen, et al.
Haematologica|October 20, 2022
Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studiesMax V Boot, Michael Schaapveld, Esther C Van den Broek, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Simple method to estimate mean heart dose from Hodgkin lymphoma radiation therapy according to simulation X-raysFrederika A van Nimwegen, David J Cutter, Michael Schaapveld, et al.
Breast Cancer Research and Treatment|August 10, 2007
The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the NetherlandsMichael Schaapveld, Otto Visser, W J Louwman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2023
Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of LifeSjoukje Lubberts, Harmke J Groot, Ronald de Wit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Risk of diabetes mellitus in long-term survivors of Hodgkin lymphomaFrederika A van Nimwegen, Michael Schaapveld, Cecile P M Janus, et al.
Blood|June 30, 2023
Risk of male breast cancer after Hodgkin lymphomaSimone de Vries, Inge M Krul, Michael Schaapveld, et al.
Pageof 14